COEP — COEPTIS THERAPEUTICS HLDGS I
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About COEPTIS THERAPEUTICS HLDGS I (COEP)
COEPTIS THERAPEUTICS HLDGS I (COEP) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $300. All data sourced from SEC 13F filings.
Based on recent institutional activity in COEP
No recent activity recorded.
How many top investors track COEP
Only 1 tracked investor report this position.
COEP Ownership Composition
How COEPTIS THERAPEUTICS HLDGS I is held across tracked investor types, based on reported 13F positions.
- Other100.0%
Tracked investors reporting COEP
- Ken GriffinDec 31, 2025Citadel AdvisorsShares10KValue$107% Portfolio0.00%
Recent activity
- No recent activity.
Frequently asked questions
- How many institutional investors hold COEP?
- 1 tracked institutional investor disclosed a position in COEP (COEPTIS THERAPEUTICS HLDGS I) in their most recent 13F filing.
- Who is the largest institutional holder of COEP?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in COEP, valued at $300.
- Did institutional ownership of COEP increase or decrease?
- Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited COEP.
- Where does this COEP ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.